Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer

David J. Goldsmith; Adrian C. Covic

doi:10.1038/ki.2011.133

Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer

David J. Goldsmith^*, Adrian C. Covic

^*Corresponding author for this work

Parhon Hosp, Dialysis & Transplantat Ctr

Research output: Contribution to journal › Editorial › peer-review

4 Citations (Scopus)

Abstract

Erythropoiesis-stimulating agents (ESAs) have been used for about three decades in chronic kidney disease patients to treat the symptoms of anemia, avoid potentially hazardous blood-product transfusions, improve some facets of quality of life, and reduce cardiovascular risk. We review a new article in which this association between stroke and ESA use is examined in a different population in a different way, but with the same worrying findings as seen in the TREAT study.

Original language	English
Pages (from-to)	237-239
Number of pages	3
Journal	Kidney International
Volume	80
Issue number	3
DOIs	https://doi.org/10.1038/ki.2011.133
Publication status	Published - Aug 2011

Keywords

ERYTHROPOIESIS-STIMULATING AGENTS
ESA

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/ki.2011.133

Cite this

@article{0ecaac98ba6b42e3aebf1c3766eb5ef2,

title = "Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer",

abstract = "Erythropoiesis-stimulating agents (ESAs) have been used for about three decades in chronic kidney disease patients to treat the symptoms of anemia, avoid potentially hazardous blood-product transfusions, improve some facets of quality of life, and reduce cardiovascular risk. We review a new article in which this association between stroke and ESA use is examined in a different population in a different way, but with the same worrying findings as seen in the TREAT study.",

keywords = "ERYTHROPOIESIS-STIMULATING AGENTS, ESA",

author = "Goldsmith, {David J.} and Covic, {Adrian C.}",

year = "2011",

month = aug,

doi = "10.1038/ki.2011.133",

language = "English",

volume = "80",

pages = "237--239",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer

AU - Goldsmith, David J.

AU - Covic, Adrian C.

PY - 2011/8

Y1 - 2011/8

N2 - Erythropoiesis-stimulating agents (ESAs) have been used for about three decades in chronic kidney disease patients to treat the symptoms of anemia, avoid potentially hazardous blood-product transfusions, improve some facets of quality of life, and reduce cardiovascular risk. We review a new article in which this association between stroke and ESA use is examined in a different population in a different way, but with the same worrying findings as seen in the TREAT study.

AB - Erythropoiesis-stimulating agents (ESAs) have been used for about three decades in chronic kidney disease patients to treat the symptoms of anemia, avoid potentially hazardous blood-product transfusions, improve some facets of quality of life, and reduce cardiovascular risk. We review a new article in which this association between stroke and ESA use is examined in a different population in a different way, but with the same worrying findings as seen in the TREAT study.

KW - ERYTHROPOIESIS-STIMULATING AGENTS

KW - ESA

U2 - 10.1038/ki.2011.133

DO - 10.1038/ki.2011.133

M3 - Editorial

SN - 0085-2538

VL - 80

SP - 237

EP - 239

JO - Kidney International

JF - Kidney International

IS - 3

ER -

Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this